<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396799</url>
  </required_header>
  <id_info>
    <org_study_id>3115A1-114</org_study_id>
    <nct_id>NCT00396799</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women</brief_title>
  <official_title>An Open-Label, Single-Dose, Randomized-to-Sequence, 2-Period, Crossover, Pivotal Bioequivalence Study Between Bazedoxifene Acetate/Conjugated Estrogens (Premarin Current Process) and Bazedoxifene Acetate/Conjugated Estrogens (Premarin New Process) Tablets Administered to Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the bioequivalence between bazedoxifene/conjugated
      estrogens tablets produced using the current manufacturing process to bazedoxifene/conjugated
      estrogens tablets produced using a new manufacturing process
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures of blood levels of endogenous estrogen hormones, conjugated estrogens and bazedoxifene.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated from reported signs and symptoms, scheduled physical examinations, gynecologic examinations, vital sign measurements, 12-lead ECG and clinical laboratory test results.</measure>
  </secondary_outcome>
  <condition>Menopause</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bazedoxifene/conjugated estrogens</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy, postmenopausal women aged 35 to 70 years and weighing at least 50 kg (approx.
             110 lbs).

          -  At least 6 months of spontaneous amenorrhea (with follicle-stimulating hormone levels
             of 39 mIU/mL or greater).

          -  Nonsmoker or smoker of fewer than 10 cigarettes per day, with ability to abstain for 5
             days.

        Exclusion Criteria

          -  Women with amenorrhea starting after 54 years of age.

          -  A history or active presence of clinically important medical diseases.

          -  Use of oral estrogen-, progestin, androgen-, or SERM-containing drug products within
             30 days before receiving study drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2006</study_first_posted>
  <last_update_submitted>March 12, 2007</last_update_submitted>
  <last_update_submitted_qc>March 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Bazedoxifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

